Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

View 0 Studies Requested

Browse Lab Results > 2015-0056

Trial Summary

About CDAS Project, PI, Publications: Serum inflammation markers and esophageal adenocarcinoma risk

Datasets


Site: Upper GI

Inclusion Criteria:

  • No Rare Cancer in Controls
  • No Prior History of Any Cancer
  • Males Only for Gastric Cases
  • Selected for Immunity Study
  • Has Serum Material
  • Has Pre-DX Most Distal Serum Available (Selected)

Matching Factors:

  • Gender
  • Race
  • Age at Draw (+/- 1 year)
  • Calendar Year of Draw
  • Study Year of Draw
  • Time of Draw (AM/PM)

Match Ratio: 1 to 1

Match Technique: Individual matching with replacement and cases as controls.

Additional Matching Comments: Match was already completed in 2015-00040


Analytes:

  • Adiponectin
  • Adipsin
  • B-Cell Attracting Chemokine 1
  • Basic Fibroblast Growth Factor
  • C-Reactive Protein
  • Chemokine (C-C Motif) Ligand 13
  • Chemokine (C-C Motif) Ligand 19
  • Chemokine (C-C Motif) Ligand 2
  • Chemokine (C-C Motif) Ligand 20
  • Chemokine (C-C Motif) Ligand 21
  • Chemokine (C-C Motif) Ligand 22
  • Chemokine (C-C Motif) Ligand 27
  • Chemokine (C-C Motif) Ligand 8
  • Chemokine (C-X-C Motif) Ligand 1
  • Chemokine (C-X-C Motif) Ligand 10
  • Chemokine (C-X-C Motif) Ligand 11
  • Chemokine (C-X-C Motif) Ligand 12
  • Chemokine (C-X-C Motif) Ligand 5
  • Chemokine (C-X-C Motif) Ligand 6
  • Chemokine (C-X-C Motif) Ligand 9
  • Chemokine (C-X3-C Motif) Ligand 1
  • Eotaxin
  • Eotaxin-2
  • Epidermal Growth Factor
  • Epidermal Growth Factor Receptor
  • Granulocyte-Colony Stimulating Factor
  • Granulocyte-Macrophage Colony Stimulating Factor
  • Interleukin 1 Receptor Antagonist
  • Interleukin 1 beta
  • Interleukin 10
  • Interleukin 11
  • Interleukin 12 p70
  • Interleukin 13
  • Interleukin 16
  • Interleukin 17 A
  • Interleukin 21
  • Interleukin 23
  • Interleukin 29
  • Interleukin 3
  • Interleukin 33
  • Interleukin 4
  • Interleukin 5
  • Interleukin 6
  • Interleukin 7
  • Interleukin 8
  • Lipocalin 2
  • Macrophage Inflammatory Protein 1 alpha
  • Macrophage Inflammatory Protein 1 delta
  • Macrophage inflammatory protein 1 beta
  • Plasminogen activator inhibitor-1
  • Resistin
  • Serum Amyloid A
  • Serum Amyloid P
  • Soluble Interleukin 4 Receptor
  • Soluble Interleukin 6 Receptor
  • Soluble Interleukin 6 beta
  • Stem Cell Factor
  • Thrombopoietin
  • Thymic Stromal Lymphopoietin
  • Thymus and Activation Regulated Chemokine
  • Transforming Growth Factor Alpha
  • Tumor Necrosis Factor Alpha
  • Tumor Necrosis Factor Beta
  • Tumor Necrosis Factor Receptor 1
  • Tumor Necrosis Factor Receptor 2
  • Tumor Necrosis Factor Receptor Superfamily, Member 10
  • Vascular Endothelial Growth Factor
  • Vascular endothelial growth factor receptor 2
  • Vascular endothelial growth factor receptor 3

Number of Cases: 63

Number of Controls: 63